Foreign investors want China exposure but get lost in A-shares, H-shares, ADRs and a wall of jargon. Three free tools to start — no account, no paywall.
Each one answers the questions foreigners actually ask.
Compare MCHI, FXI, KWEB, ASHR, CQQQ, GXC side-by-side. Filter by strategy or onshore/offshore, sort by fee or size, tick 2–3 to compare. Live prices when the network allows.
Type BABA, PDD, JD, NIO… and see the key mitigant — a Hong Kong listing — plus HFCAA/PCAOB status and the conversion path if delisting ever forces the issue.
"How do I actually buy?" Pick your region, investor type and target (ETF / ADR / H-share / A-share) to see the realistic access path and example platforms.
Type any company or code — Alibaba, Tencent, BYD, 0700.HK, BABA — and see its A-share, H-share and ADR codes together, plus where a foreigner can buy.
Plain-English answers to the questions foreigners ask before investing.
The simplest path in: start with a China ETF, then decide on ADRs or Hong Kong shares.
Same company, two markets, sometimes two prices — and which is easier to buy.
What HFCAA/PCAOB mean, why a HK listing is the safety net, and how conversion works.
MCHI vs FXI vs KWEB vs ASHR vs CQQC — what each tracks and how to choose.
The map that makes every other tool make sense.
Read the full Market 101 → (four-way comparison table, how foreigners actually get in, and a mini glossary).
Yes. MCHI, FXI, KWEB, ASHR, CQQQ and GXC all trade on US exchanges, so any broker offering US-listed ETFs can access them. No Chinese bank account needed. (EU/UK retail: note PRIIPs limits on US-domiciled ETFs — use UCITS instead.)
ASHR (Xtrackers Harvest CSI 300) is the onshore one — it tracks the CSI 300 of mainland A-shares. The others mostly hold Hong Kong-listed H-shares and US ADRs.
They trade on regulated exchanges with transparent pricing, but carry specific risks: policy shifts, geopolitics, currency, and (for ADR-heavy funds) delisting/VIE risk. Most foreign advisors suggest a modest slice (~5–15% of an equity portfolio) rather than a dominant weight.
The Holding Foreign Companies Accountable Act (2020) can delist a firm after two consecutive years of denied PCAOB audit inspection. Access was secured in 2022, but political pressure re-emerged in 2025–26. The mitigant is a Hong Kong listing — dual-listed names can usually convert to HK shares.